Apixaban, Anti-Xa, Plasma
Use
Measurement of apixaban concentration is useful in selected clinical situations such as renal insufficiency, assessment of compliance, periprocedural drug concentration measurement, suspected overdose, advanced age, and extremes of body weight ([mayocliniclabs.com](https://www.mayocliniclabs.com/test-catalog/overview/65848?utm_source=openai))
Special Instructions
Not provided.
Limitations
Routine monitoring of apixaban is not indicated. Therapeutic reference ranges have not been established, though peak and trough concentrations from clinical trials are available. The lower limit of detection is 10 ng/mL. Apixaban concentration may be affected by drug interactions and impaired liver or kidney function ([mayocliniclabs.com](https://www.mayocliniclabs.com/test-catalog/overview/65848?utm_source=openai))
New York Approved
Methodology
Immunoassay (Chromogenic Assay)
Biomarkers
Unknown biomarker
Other
LOINC Codes
- 74214-8 - Apixaban PPP Chro-mCnc
- 74214-8 - Apixaban PPP Chro-mCnc
- 69049-5 - Coagulation specialist review
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL
Minimum Volume
0.5 mL
Container
Light‑blue top (3.2% sodium citrate) tube; plastic vial
Collection Instructions
Collect platelet‑poor plasma. Specimen collected 2 to 4 hours post‑dose (peak) or just prior to next dose (trough). Centrifuge, transfer plasma into plastic vial, centrifuge again; freeze immediately, ideally ≤‑40 °C, no longer than 4 hours after collection ([hematology.testcatalog.org](https://hematology.testcatalog.org/show/APIXA?utm_source=openai))
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 42 days (Plasma Na Cit frozen) ([testcatalog.org](https://www.testcatalog.org/show/APIXA?utm_source=openai)) |